Cara Therapeutics Has Risen ~18% in January



Stock performance

Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31, which represents ~18% growth YTD (year-to-date). On January 2, Cara Therapeutics’ stock price grew ~12.00% to $14.56 from the close of $13.00 on December 31.

On January 18, Cara Therapeutics’ stock price closed at $15.35, which is ~37% below its 52-week high of $24.30 on September 21, 2018. The company hit its 52-week low of $11.46 on April 3, 2018.

Cara Therapeutics is focused on developing new drug candidates for pruritus and pain management. Cara Therapeutics’ Korsuva (CR845/difelikefalin) is in its phase 3 pivotal trial for evaluating its efficacy in treating pruritus.

Article continues below advertisement

Analysts’ recommendations

Among the ten analysts tracking Cara Therapeutics is January, four recommended a “strong buy,” five recommended a “buy,” and one recommended a “hold.” On January 21, Cara Therapeutics had a consensus 12-month target price of $26.1, which represents an ~70.30% return on investment over the next 12 months.

Peers’ ratings

Among the five analysts tracking INSYS Therapeutics (INSY) in January, 80% recommended a “buy.” Among the five analysts tracking Zynerba Pharmaceuticals (ZYNE), ~80% recommended a “buy.” In January, among the 13 analysts tracking GW Pharmaceuticals, ~85% recommended a “buy.”

On January 21, INSYS Therapeutics, Zynerba Pharmaceuticals, and GW Pharmaceuticals had consensus 12-month target prices of $8.4, $18.4, and $173.17, respectively, which is an ~90.91%, ~373.01%, and ~26.13% return on investment over the next 12 months.


More From Market Realist